PFE
Pfizer Inc.
$28.07
장중 · Vol 2.28M · 52주 $23.58–$28.75 · 기준 2026. 8. 21. PM 3:59 ET
일봉 $27.82 · Aug 31, 2026
PFE 가격 추세
종가
$27.82
시가
$27.85
고가
$27.90
저가
$27.64
30초 브리핑
PFE 오늘의 판단 요약
보유 데이터를 비교 가능한 문장으로 해석한 요약입니다.
52주 범위의 87%
연중 고점권입니다. 추세 강도와 돌파 실패 위험을 함께 확인하세요.
Forward P/E 9.8배
선행 P/E가 낮아 시장은 이익 증가를 반영하고 있습니다.
20일 평균의 1.4배
거래량은 최근 평균 범위입니다.
2026-11-03
실적 전후 변동성 확대 가능성이 있으므로 컨센서스 범위와 옵션 기대변동을 함께 보세요.
펀더멘털 기준 Sep 1, 2026 · 규칙 기반 요약이며 투자 조언이 아닙니다.
핵심 통계
PFE 일봉·펀더멘털 스냅샷 기준 주요 지표
펀더멘털 스냅샷 Sep 1, 2026
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
66 Hudson Boulevard East · New York, NY, United States · 직원 75,000명
시가총액
$162.21B
Trailing P/E
37.0
최근 12개월 이익 기준
Forward P/E
9.8
이익 증가 기대 반영
EPS (TTM)
$0.77
배당 수익률
6.15%
배당성향
226.3%
지속 가능성 점검
베타
0.28
시장보다 방어적
ROE
5.0%
P/B
1.90
EV/EBITDA
8.3
52주 범위
$23.58 – $28.75
현재 위치 87%
거래량
37.07M
20일 평균 27.08M · 1.4배
애널리스트 의견
매수 36%
총 28명 · 0m
DITM LEAPS Analysis
PFE 장기 DITM 콜옵션을 진입 적합도 순으로 비교
| Contract | Expiry | Strike | Price | Lev. | Delta | Extrinsic | Spread | IV | OI | Score | 상세 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PFE280121C00020000 | 1/21/28 · 1.4Y | $20.00 | $8.85 | 2.9x | 0.9127 | 4.4% | 6.78% | 29.81% | 19,148 | 98.09 | |
| PFE271217C00020000 | 12/17/27 · 1.3Y | $20.00 | $8.92 | 2.9x | 0.9108 | 5.2% | 5.04% | 30.88% | 2,521 | 95.80 | |
| PFE280121C00022000 | 1/21/28 · 1.4Y | $22.00 | $7.00 | 3.5x | 0.8742 | 7.7% | 12.86% | 27.59% | 5,540 | 90.81 | |
| PFE271217C00022000 | 12/17/27 · 1.3Y | $22.00 | $6.85 | 3.6x | 0.8679 | 5.7% | 18.98% | 29.20% | 2,958 | 88.49 | |
| PFE270917C00020000 | 9/17/27 · 1.0Y | $20.00 | $8.60 | 3.0x | 0.9098 | 1.6% | 11.63% | 33.50% | 1 | 87.31 | |
| PFE270917C00023000 | 9/17/27 · 1.0Y | $23.00 | $6.15 | 3.9x | 0.8519 | 11.2% | 9.76% | 28.27% | 41 | 83.32 | |
| PFE271217C00015000 | 12/17/27 · 1.3Y | $15.00 | $13.50 | 1.9x | 0.8891 | 0.3% | 37.04% | 80.25% | 226 | 75.90 | |
| PFE280121C00025000 | 1/21/28 · 1.4Y | $25.00 | $5.10 | 4.4x | 0.7836 | 32.2% | 5.88% | 25.78% | 18,103 | 75.21 | |
| PFE271217C00025000 | 12/17/27 · 1.3Y | $25.00 | $5.02 | 4.4x | 0.7771 | 31.1% | 10.95% | 27.17% | 12,737 | 72.99 | |
| PFE270917C00025000 | 9/17/27 · 1.0Y | $25.00 | $4.58 | 4.9x | 0.7836 | 24.4% | 16.39% | 26.66% | 48 | 70.25 |
재무제표
PFE 연간 손익·현금흐름·재무상태
매출 성장률
-1.6%
최근 연간 YoY
EPS 성장률
-3.5%
최근 연간 YoY
영업이익률
27.8%
최근 연간
FCF 마진
14.5%
잉여현금흐름 / 매출
매출 추세
순이익 추세
잉여현금흐름 추세
| 항목 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| 매출 | $62.58B-1.6% | $63.63B+6.8% | $59.55B-41.1% | $101.17B |
| 매출총이익 | $46.51B+1.6% | $45.78B+32.3% | $34.60B-48.2% | $66.83B |
| 영업이익 | $17.41B+16.5% | $14.94B+238.2% | $4.42B-88.4% | $38.12B |
| 순이익 | $7.77B-3.2% | $8.03B+279.0% | $2.12B-93.2% | $31.37B |
| 희석 EPS | $1.36-3.5% | $1.41+281.1% | $0.37-93.2% | $5.47 |
| EBITDA | $16.78B-7.4% | $18.13B+89.7% | $9.56B-76.7% | $41.03B |
| 영업현금흐름 | $11.70B-8.2% | $12.74B+46.5% | $8.70B-70.3% | $29.27B |
| 잉여현금흐름 | $9.07B-7.7% | $9.84B+105.2% | $4.79B-81.6% | $26.03B |
| 총자산 | $208.16B-2.5% | $213.40B-5.8% | $226.50B+14.9% | $197.21B |
| 총부채 | $63.96B+0.5% | $63.65B-10.2% | $70.84B+103.2% | $34.86B |
최신 연도 우선 · 작은 퍼센트는 직전 연도 대비 변화입니다.
캘린더
PFE 실적·배당 일정
매출 하단
$14.98B
EPS 하단
$0.59
매출 상단
$16.85B
배당 지급일
2026-09-01
오늘
실적 발표일
2026-11-03
D-63
EPS 상단
$0.94
매출 컨센서스
$15.95B
EPS 컨센서스
$0.76
배당락일
2026-07-24
39일 전
최근 배당
| 배당락일 | 주당 배당 |
|---|---|
| Jul 24, 2026 | $0.4300 |
| May 8, 2026 | $0.4300 |
| Jan 23, 2026 | $0.4300 |
| Nov 7, 2025 | $0.4300 |
| Jul 25, 2025 | $0.4300 |
| May 9, 2025 | $0.4300 |
| Jan 24, 2025 | $0.4300 |
| Nov 8, 2024 | $0.4200 |
뉴스
PFE 관련 최신 기사
규제·법률Pfizer (PFE) Reaches Confidential Settlement In Depo Provera Litigation
Pfizer (NYSE:PFE) has reached a confidential settlement covering federal lawsuits over its Depo-Provera contraceptive and alleged intracranial meningioma risk. The agreement reportedly addresses more than 6,000 cases, with financial terms not disclosed and no admission of liability by Pfizer. The resolution closes a multi year legal overhang tied to Depo-Provera and brings clarity to a significant product liability dispute. This kind of large scale legal settlement can shift how investors...
Simply Wall St. · Aug 31, 2026
제품·기술From Padcev to PF-08634404: Pfizer's Oncology Growth Push
PFE's oncology growth is led by Padcev, while a broad pipeline and label expansions aim to fuel longer-term gains.
Zacks · Aug 31, 2026
- 제품·기술
Pfizer and Starbucks: One Turnaround Is Built to Last, and One Isn’t
Pfizer and Starbucks both raised their outlooks this summer, but a louder recovery and a quieter one are not the same thing, and for investors who need a portfolio to fund actual withdrawals, the difference matters enormously.
24/7 Wall St. · Aug 31, 2026
제품·기술Is Pfizer Stock Underperforming the S&P 500?
PFE has underperformed the broader market over the past year, while analysts remain moderately optimistic about its future prospects.
Barchart · Aug 31, 2026
제품·기술Did A Product Swap Fuel JNJ Stock’s 54% Surge?
The signs were not in the headline growth rate but in which two products were trading places.
Trefis · Aug 28, 2026
실적Can Merck Stock Outrun Its Pipeline?
Revenue grew at its usual pace over the past year while the stock outran its biggest peers, and the gap sits in a run of clinical readouts that landed early.
Trefis · Aug 28, 2026
- 일반
Pfizer's Updated COVID Shot Ships Into a Smaller Market
The XFG-adapted vaccine targets older and high-risk patients, with deliveries to pharmacies and clinics beginning immediately.
GuruFocus.com · Aug 28, 2026
제품·기술BioNTech Terminates Phase 2 Colorectal Cancer Clinical Trial; Shares Fall
BioNTech (BNTX) shares slumped Friday after the company said it is terminating a mid-stage clinical
MT Newswires · Aug 28, 2026
제품·기술BioNTech Tumbles 8% as Colorectal Cancer Vaccine Trial Fails, Moderna Drops 6%, Pfizer Holds Flat
BioNTech's colorectal cancer vaccine just collapsed in a Phase 2 trial, dragging Moderna down with it despite last week's melanoma triumph, and the fallout is forcing investors to rethink how far mRNA technology can actually reach into solid tumors.
24/7 Wall St. · Aug 28, 2026
제품·기술2 Cash-Producing Stocks with Solid Fundamentals and 1 We Turn Down
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
StockStory · Aug 28, 2026
홀더
PFE 내부자·기관 보유 현황
최신 보고 목록 기준이며 실제 거래 시점과 보고일 사이에는 시차가 있습니다.
기관 보유
69.2%
기관 보유 (유동주식)
69.2%
내부자 보유
0.1%
기관 수
3,644
주요 기관 홀더
| 홀더 | 주식 수 | 평가액 | 지분 | 변동 | 보고일 |
|---|---|---|---|---|---|
| Blackrock Inc. | 529.67M | $15.07B | 9.3% | 6.3% | Jun 30, 2026 |
| Vanguard Capital Management LLC | 372.15M | $10.59B | 6.5% | 0.7% | Jun 30, 2026 |
| State Street Corporation | 307.09M | $8.74B | 5.4% | 1.8% | Jun 30, 2026 |
| Geode Capital Management, LLC | 135.28M | $3.85B | 2.4% | 1.3% | Jun 30, 2026 |
| Vanguard Portfolio Management LLC | 119.24M | $3.39B | 2.1% | 2.1% | Jun 30, 2026 |
| Fisher Asset Management, LLC | 109.07M | $3.10B | 1.9% | 3.9% | Jun 30, 2026 |
| Morgan Stanley | 96.35M | $2.74B | 1.7% | 4.0% | Jun 30, 2026 |
| NORGES BANK | 61.51M | $1.75B | 1.1% | -16.4% | Jun 30, 2026 |
| Northern Trust Corporation | 59.08M | $1.68B | 1.0% | -4.7% | Jun 30, 2026 |
| Bank Of New York Mellon Corporation | 57.88M | $1.65B | 1.0% | 7.4% | Jun 30, 2026 |
면책조항: 증시가격은 모든 주식 시장의 최신 증시가격을 표시하는 것은 아니며, 정보가 지연되거나 잘못될 수 있습니다. 거래 목적이나 조언이 아닌 정보 제공 목적으로만 제공됩니다.